01:39 PM EDT, 07/09/2024 (MT Newswires) -- Athira Pharma ( ATHA ) said Tuesday it has dosed the last patient in the phase 2/3 for fosgonimeton in patients with mild-to-moderate Alzheimer's disease.

The company aims to release top-line results by the end of Q3 and present the full data set on Oct. 29.

The trial is studying fosgonimeton in approximately 315 mild-to-moderate Alzheimer's patients not on acetylcholinesterase inhibitors, through daily subcutaneous injections of 40mg over 26 weeks.

Athira Pharma ( ATHA ) shares jumped almost 23% in recent trading.

Price: 3.21, Change: +0.59, Percent Change: +22.52